The interim outcome of a clinical trial with the ‘ process upgraded’ recombinant Hepatitis B batches confirms that the immunogenicity of the current HBVAXPRO vaccine is at the historic standard, and provides evidence for a consistent trend to higher GMTs with HBVAXPRO manufactured with the process modification.